Keyword: Kadcyla

We may be focusing on our forecasts for the year ahead with today's issue, but here's some Friday news we thought you shouldn't miss.

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

With a new FDA nod in postsurgery patients—and Herceptin biosimilars looming—Roche's Kadcyla has more space to run.

Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.

Roche could use a speedy Kadcyla label expansion to help quiet concerns about mounting biosimilar competition to its aging blockbusters.

With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.

Cost watchdogs in England and pharma don't always agree, but the sides are celebrating two new deals on Merck KGaA's Mavenclad and Roche's Perjeta.

Roche has sealed a deal to provide Gazyvaro to U.K. patients through the revamped Cancer Drugs Fund.